Market Trends of Global Constipation Treatment Industry
This section covers the major market trends shaping the Constipation Treatment Market according to our research experts:
Peripherally Acting Mu-Opioid Receptor Antagonists are Expected to Attain Significant Growth in the Constipation Treatment Market During the Forecast Period
Peripherally Acting Mu-Opioid Receptor Antagonists are expected to attain a significant growth rate over the forecast period. This growth is owing to the availability of various types of products launched by the key players that are suitable for various symptoms in the OIC and the rise in research activities in the segment. A few of the drugs that are readily available in the market for OIC indication are Methylnaltrexone (Relistor), Naldemedine (Symproic), Naloxegol (Movantik), and Alvimopan (Entereg).
Moreover, the study titled "Peripheral acting mu-opioid receptor antagonists in the treatment of opioid-induced constipation: a review," published in RESED Journal in September 2020, studied the recently launched Mu-opioid receptor antagonists for their safety and efficacy and concluded that PAMORA had shown efficacy in the treatment of OIC when compared to placebo and in different patient populations, as well as in the case of Naloxegol when compared to laxatives. Metilnaltrexona was studied and approved for patients with advanced cancer pain or other diseases, whereas Alvimopan and Naloxegol were for non-cancer patients. Thus increasing availability of Mu-opioid Receptor Antagonists anticipated the segment growth over the forecast period.
Furthermore, in February 2021, RedHill Biopharma Ltd. signed agreements with Cosmo Pharmaceuticals NV to manufacture two key products; Movantik(μ-opioid receptor antagonist), and RHB-204, currently in a Phase 3 United States study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
Thus, owing to the abovementioned factors, the Peripherally Acting Mu-Opioid Receptor Antagonists segment is expected to grow and contributes to global market revenue over the forecast period.
North America is Expected to Dominate the Constipation Treatment Market During the Forecast Period
North America is expected to dominate the global constipation treatment market, and it is mainly driven due to the increasing prevalence of chronic constipation and growing investment in healthcare. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), data updated in December 2021, constipation affects people of all ages and populations in the United States. Constipation affects about 16 out of every 100 persons. Constipation affects about 33 out of every 100 persons aged 60 and up. Therefore, the growing incidence rate of constipation among people is expected to increase the demand for effective treatment, in turn, fueling the target market growth in the studied period.
Furthermore, the United States holds the largest market share in the North American region owing to factors such as the presence of a large number of market players manufacturing medications for constipation. In addition to this, several market players are engaged in the product launches, thereby contributing to the region's growth. For instance, in March 2021, Knight Therapeutics Inc. announced the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. The company has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered with Ardelyx, Inc. As a result, all the aforementioned factors are likely to contribute to this region's strong growth over the forecast period.
